(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.



Fig. 1. ERK-MAPK-dependent expression of c-JUN and FRA-1 in colon carcinoma cells. (A) Immunoblot analysis of ERK2 and phospho-ERK1/2 proteins in HCT-116 and BE cells 2, 4, 8 and 24 hours after the addition of the MEK inhibitor U0126, or the vehicle alone (ethanol). (B) Immunoblot analysis of FRA-1, c-JUN, c-FOS, JUNB and FRA-2 protein expression in HCT-116 and BE cells 2, 4, 8 and 24 hours after addition of the MEK inhibitor U0126. (C) Immunoblot analysis of FRA-1, c-JUN, ERK2 and phospho-ERK1/2 proteins in BE cells, HCT-116 and LS174T colon carcinoma cells. (D) Northern blot analysis of FRA-1, c-JUN and GAPDH mRNA expression in HCT-116 and BE cells 2, 4, 8 and 24 hours after addition of the MEK inhibitor U0126. (E) Immunoblot analysis of FRA-1, c-JUN, ERK2 and phospho-ERK1/2 proteins in BE cells 2, 4, 8 and 24 hours after the addition of 1 µM of the MEK inhibitor PD184352.